Schizophrenia
Conditions
Brief summary
The objective of the study is to investigate the efficacy, safety and tolerability of BI 409306 once daily compared with placebo given for 28 weeks in patients with schizophrenia on antipsychotic treatment. The study is designed to show superiority of BI 409306 over placebo in preventing relapse of schizophrenia symptoms.
Interventions
DRUGBI 409306
28 week treatment period
DRUGPlacebo
28 week treatment period
Sponsors
Boehringer Ingelheim
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10) diagnosis of schizophrenia \>= one year prior to randomisation. * Outpatients in the stable phase of illness, as assessed by the investigator after review of medical records or documented discussion with treating clinician. * Patients currently taking a stable dose of antipsychotic medication(s) for at least 12 weeks prior to randomisation. * Detectable level of current antipsychotic medication(s) in plasma from blood drawn at Visit 1 (unless no assay is available for the antipsychotic(s) currently prescribed). * Patients who have experienced at least 2 relapses within the past 5 years or at least 1 relapse if they were diagnosed less than 3 years ago. Relapse is defined as the patient having any of the following using the above number of relapses and time frames: * Hospitalization for psychosis (involuntary or voluntary admission), intensive outpatient therapy or use of home treatment as an alternative to hospitalization (verified via medical record). * Emergency Department visit for worsening schizophrenia symptoms (verified via medical record). * Deliberate self-injury and/or violent behaviour resulting in significant injury to another person or property (verified by police record or treating mental health provider written record or documented phone conversation). * Change in the patient's antipsychotic medication or increase in antipsychotic medication dosage due to worsening of schizophrenia symptoms (verified by pharmacy records or treating mental health provider written record or documented phone conversation). * Clinical Global Impressions-Severity (CGI-S) score ≤4 at Visit 1 and 2. * Positive and Negative Syndrome Scale (PANSS) total score \<80 and a score of ≤ 4 on individual PANSS items conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content at Visit 1. * Of full age (according to local legislation, usually ≥ 18 years) and ≤ 55 years at the time of informed consent. * Patients must have an identified informant who will be consistent throughout the study. * Patients who report living at the same address for the 3 months prior to randomisation. * Male or female patients. \-- Female patients of childbearing potential must be ready and able to use highly effective methods of birth control per International Conference on Harmonisation (ICH) M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. Patients must agree to use birth control throughout the trial and for at least 28 days after treatment has ended. Acceptable methods of birth control include combined estrogen-progestin oral, intravaginal or transdermal contraceptives, progestogen-only oral, injectable or implantable contraceptives, intrauterine devices (IUDs), intrauterine hormone releasing systems (IUSs), bilateral tubal occlusion, vasectomized sexual partner, and complete sexual abstinence (if acceptable by local health authorities) is allowed when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptom-thermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. * Male patients who are able to father a child must be ready and able to be abstinent or use adequate contraception for the duration of study participation and for at least 28 days after treatment has ended. * Signed and dated written informed consent in accordance with International Conference on Harmonisation - Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial. If the patient has a legal representative, then this legal representative must give written informed consent as well.
Exclusion criteria
* Patients treated with more than two antipsychotic medications (including more than two dosage forms). * Patients who are currently being treated with clozapine, or who have been treated with clozapine in the past 5 years. * Patients with a categorical diagnosis of another current major psychiatric disorder per the Mini-international neuropsychiatric Interview (M.I.N.I.). * Homicidal behaviour (in the investigator's judgement) in the past 2 years. * Any suicidal behavior in the past 2 years (i.e. actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behavior). * Any suicidal ideation of type 4 or 5 in the Columbia Suicide Severity Rating Scale (CSSRS) in the past 3 months (i.e. active suicidal thought with intent but without specific plan, or active suicidal thought with plan and intent). * In the judgment of the investigator, any clinically significant finding from the physical examination or laboratory value deviating from normal or any evidence of a clinically significant concomitant disease or any other clinical condition that would jeopardize a patient's safety while participating in the clinical trial. * Other known neurological diseases (including but not limited to any kind of seizures or stroke). * Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening, except appropriately treated basal cell carcinoma of the skin or in situ carcinoma of uterine cervix. * Planned elective surgery requiring general anesthesia, or hospitalization for more than 1 day during the study period. * Significant history of drug or alcohol dependence or abuse (Substance Use Disorder as defined in Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) or ICD-10) within the last six months prior to informed consent. (Not including caffeine or nicotine). * Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial. * Patients taking strong or moderate CYP1A2 inhibitors who are also a CYP2C19 Poor Metabolizer (PM). Patients taking medication known to be strong or moderate inhibitors of CYP1A2 must be prospectively genotyped to ensure they are not poor metabolizers of CYP2C19. (A list of CYP1A2 and CYP2C19 inhibitors can be found in the Investigator Site File (ISF)). * Patients taking strong or moderate CYP1A2 inhibitors who are also taking concomitant strong or moderate CYP2C19 inhibitors. (A list of CYP1A2 and CYP2C19 inhibitors can be found in the ISF) * Patients with a history of moderate to severe hepatic impairment (Child-Pugh B / C). * Patients with a history of moderate to severe renal impairment (Stage 3 - 5). * Women who are pregnant, nursing, or who plan to become pregnant while in the trial. * In the judgment of the investigator, inability of the patient to comply with the clinical trial procedures. * Currently enrolled in another investigational device or drug study, or less than 6 months from Visit 1 since ending another investigational device or drug study(s), or participation in \> 2 investigational drug clinical trials in the past 2 years. * Previous randomisation in any BI 409306 study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence Rate of First Relapse After 28 Weeks of Treatment | 28 weeks | The incidence rate of first relapse after 28 weeks of treatment is reported. For each treatment group, the incidence rate was calculated as the number of events / sum of the observational time (patient year) over all participants in this treatment group. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Clinical Global Impressions-Severity (CGI-S) Scale Score After 28 Weeks of Treatment | At baseline and at Week 28 | Clinical Global Impressions-Severity (CGI-S): One-item evaluation completed by the clinician to measure the severity of psychopathology. The CGI-S score ranges from 1 (normal) through to 7 (most severely ill). The higher the score, the worse the psychopathology. |
| Patient Global Impressions-Improvement (PGI-I) Scale Score After 28 Weeks of Treatment | At Week 28 | Patient Global Impressions-Improvement (PGI-I): One-item evaluation completed by the patient to assess their overall evaluation of his/her status compared to how they felt at randomisation. The PGI-I score ranges from 1 (Very much better) through to 7 (Very much worse). The higher the score, the worse the improvement. |
| Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Positive Symptoms Score After 28 Weeks of Treatment | At baseline and at Week 28. | Positive and Negative Syndrome Scale (PANSS): assesses the severity of psychotic symptoms and progression of disease. The PANSS positive symptoms score is the sum of scores from 7 Items where each item has a minimum score 1 (better outcome) and maximum score 7 (worse outcome). The PANSS positive symptoms score ranges from 7 (less severe the disease) to 49 (more severe the disease). |
| Change From Baseline in Personal and Social Performance Scale (PSP) Score After 28 Weeks of Treatment | At baseline and at Week 28 | Personal and Social Performance scale (PSP): The PSP is a 100-point, single item, clinician rated scale to assess 4 domains of social functioning (Four domains over the past month: (1) socially useful activities, (2) personal and social relationships, (3) self-care and (4) disturbing and aggressive behaviors.) in patients with schizophrenia. The PSP score is a single score ranging from 1 to 100. Higher scores represent better personal and social functioning. |
| Incidence Rate of New Prescription or Increase in Dose of an Ongoing Antipsychotic Medication | 28 weeks | The incidence rate of new prescription or increase in dose of an ongoing antipsychotic medication is reported. For each treatment group, the incidence rate was calculated as the number of events / sum of the observational time (patient year) over all participants in this treatment group. |
| Incidence Rate of Suicidal Ideation and Behaviour (Assessed by Columbia Suicide Severity Rating Scale (C-SSRS)) After 28 Weeks of Treatment | 28 weeks | Columbia Suicide Severity Rating Scale (C-SSRS): suicide risk assessment. At a minimum, the interview consists of 2 screening questions related to suicidal ideation and 4 related to suicidal behavior, and may be expanded to up to 17 items in case of positive responses. Free text entries are allowed. Suicidal behavior is collected in nominal scale as presence/absence of actual attempts, non-suicidal self-injurious behavior, interrupted attempts, aborted attempts, preparatory acts or behavior, and any suicidal behavior. Suicidal ideation is rated on a 6-point scale from 0 (No ideation present) to 5 (Active ideation with plan and intent). A score of 4 or 5 on this scale indicates serious suicidal ideation. For each treatment group, the incidence rate was calculated as the number of events / sum of the observational time (patient year) over all participants in this treatment group. |
Countries
Canada, France, Japan, South Korea, Spain, Taiwan, United States
Participant flow
Recruitment details
This Phase II trial aimed to evaluate the impact of 28-week treatment with BI 409306 (added to standard antipsychotic medication) compared with placebo on preventing relapse in patients with schizophrenia.
Pre-assignment details
All subjects were screened for eligibility prior to participation in the trial. Subjects attended a specialist site which ensured that they (the subjects) strictly met all inclusion and none of the exclusion criteria. Subjects were not to be allocated to a treatment group if any of the entry criteria were violated.
Participants by arm
| Arm | Count |
|---|---|
| BI 409306 25 mg 1 film-coated tablet of 25 milligrams (mg) of BI 409306 plus 1 tablet of 50 mg matching placebo were administered orally once daily for a treatment period of 28 weeks, followed by a withdrawal/taper period of 7 days, followed by a follow-up period of 3 weeks.
Participants were randomized to either withdrawal or taper period in 1:1 ratio at the randomization of treatment groups.
Withdrawal period: 4 tablets of 10 mg placebo once daily (q.d.) on Day 1 of withdrawal period; 3 tablets of 10 mg placebo q.d. on Day2-3 of withdrawal period; 2 tablets of 10mg placebo q.d. on Day 4-5 of withdrawal period; 1 tablet of 10mg placebo q.d. on Day 6-7 of withdrawal period.
Taper period: 2 tablets of 10 mg BI 409306 and 2 tablets of placebo q.d. on Day 1 of the taper period; 2 tablets of 10 mg BI 409306 and 1 tablet of placebo q.d. on Day 2-3 of taper period; 1 tablet of 10 mg BI 409306 and 1 tablet of placebo q.d. on Day 4-5 of taper period; 1 tablet of 10 mg BI 409306 q.d. on Day 6-7 of taper period. | 89 |
| BI 409306 50 mg 1 film-coated tablet of 50 milligrams (mg) of BI 409306 plus 1 tablet of 25 mg matching placebo were administered orally once daily for a treatment period of 28 weeks, followed by a withdrawal/taper period of 7 days, followed by a follow-up period of 3 weeks.
Participants were randomized to either withdrawal or taper period in 1:1 ratio at the randomization of treatment groups.
Withdrawal period: 4 tablets of 10 mg placebo once daily (q.d.) on Day 1 of withdrawal period; 3 tablets of 10 mg placebo q.d. on Day2-3 of withdrawal period; 2 tablets of 10mg placebo q.d. on Day 4-5 of withdrawal period; 1 tablet of 10mg placebo q.d. on Day 6-7 of withdrawal period.
Taper period: 4 tablets of 10 mg BI 409306 q.d. on Day 1 of taper period; 3 tablets of 10 mg BI 409306 q.d. on Day 2-3 of taper period; 2 tablets of 10 mg BI 409306 q.d. on Day 4-5 of taper period; 1 tablet of 10 mg BI 409306 q.d. on Day 6-7 of taper period. | 88 |
| Placebo 1 film-coated tablet of 25 milligrams (mg) of matching Placebo plus 1 tablet of 50 mg matching placebo were administered orally once daily for a treatment period of 28 weeks, followed by a withdrawal/taper period of 7 days, followed by a follow-up period of 3 weeks.
Participants were randomized to either withdrawal or taper period in 1:1 ratio at the randomization of treatment groups.
Both withdrawal and taper periods: 4 tablets of 10 mg placebo once daily (q.d.) on Day 1 of withdrawal/taper period; 3 tablets of 10 mg placebo q.d. on Day 2-3 of withdrawal/taper period; 2 tablets of 10mg placebo q.d. on Day 4-5 of withdrawal/taper period; 1 tablet of 10mg placebo q.d. on Day 6-7 of withdrawal/taper period. | 87 |
| Total | 264 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Adverse Event | 7 | 11 | 12 |
| Overall Study | COVID-19 restrictions | 3 | 0 | 1 |
| Overall Study | Investigator's decision | 0 | 0 | 2 |
| Overall Study | Lost to Follow-up | 2 | 6 | 4 |
| Overall Study | Non-compliance | 2 | 5 | 0 |
| Overall Study | Protocol Violation | 2 | 2 | 0 |
| Overall Study | System error | 0 | 0 | 2 |
| Overall Study | Withdrawal by Subject | 11 | 16 | 13 |
Baseline characteristics
| Characteristic | BI 409306 25 mg | BI 409306 50 mg | Placebo | Total |
|---|---|---|---|---|
| Age, Continuous | 38.4 Years STANDARD_DEVIATION 9.8 | 41.9 Years STANDARD_DEVIATION 9.6 | 40.5 Years STANDARD_DEVIATION 9.8 | 40.3 Years STANDARD_DEVIATION 9.8 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 10 Participants | 15 Participants | 15 Participants | 40 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 75 Participants | 69 Participants | 68 Participants | 212 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 4 Participants | 4 Participants | 4 Participants | 12 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 23 Participants | 20 Participants | 20 Participants | 63 Participants |
| Race (NIH/OMB) Black or African American | 36 Participants | 37 Participants | 32 Participants | 105 Participants |
| Race (NIH/OMB) More than one race | 1 Participants | 1 Participants | 2 Participants | 4 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 2 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 6 Participants | 4 Participants | 8 Participants | 18 Participants |
| Race (NIH/OMB) White | 23 Participants | 24 Participants | 25 Participants | 72 Participants |
| Sex: Female, Male Female | 29 Participants | 36 Participants | 32 Participants | 97 Participants |
| Sex: Female, Male Male | 60 Participants | 52 Participants | 55 Participants | 167 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 89 | 1 / 88 | 0 / 87 | 1 / 264 |
| other Total, other adverse events | 30 / 89 | 25 / 88 | 19 / 87 | 74 / 264 |
| serious Total, serious adverse events | 9 / 89 | 7 / 88 | 12 / 87 | 28 / 264 |
Outcome results
Primary
Incidence Rate of First Relapse After 28 Weeks of Treatment
The incidence rate of first relapse after 28 weeks of treatment is reported. For each treatment group, the incidence rate was calculated as the number of events / sum of the observational time (patient year) over all participants in this treatment group.
Time frame: 28 weeks
Population: Full analysis set (FAS): the FAS includes all patients in the treated set with at least 1 baseline and post-baseline measurement of any type.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| BI 409306 25 mg | Incidence Rate of First Relapse After 28 Weeks of Treatment | 0.527 Events per patient-years |
| BI 409306 50 mg | Incidence Rate of First Relapse After 28 Weeks of Treatment | 0.434 Events per patient-years |
| BI 409306 Pooled | Incidence Rate of First Relapse After 28 Weeks of Treatment | 0.482 Events per patient-years |
| Placebo | Incidence Rate of First Relapse After 28 Weeks of Treatment | 0.496 Events per patient-years |
p-value: 0.773595% CI: [0.585, 2.056]Regression, Cox
p-value: 0.780995% CI: [0.468, 1.77]Regression, Cox
p-value: 0.986295% CI: [0.576, 1.753]Regression, Cox
Secondary
Change From Baseline in Clinical Global Impressions-Severity (CGI-S) Scale Score After 28 Weeks of Treatment
Clinical Global Impressions-Severity (CGI-S): One-item evaluation completed by the clinician to measure the severity of psychopathology. The CGI-S score ranges from 1 (normal) through to 7 (most severely ill). The higher the score, the worse the psychopathology.
Time frame: At baseline and at Week 28
Population: Full analysis set (FAS): the FAS includes all patients in the treated set with at least 1 baseline and post-baseline measurement of any type. Only participants with non-missing results were included in the analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| BI 409306 25 mg | Change From Baseline in Clinical Global Impressions-Severity (CGI-S) Scale Score After 28 Weeks of Treatment | -0.15 Score on a scale | Standard Deviation 0.758 |
| BI 409306 50 mg | Change From Baseline in Clinical Global Impressions-Severity (CGI-S) Scale Score After 28 Weeks of Treatment | -0.22 Score on a scale | Standard Deviation 0.839 |
| BI 409306 Pooled | Change From Baseline in Clinical Global Impressions-Severity (CGI-S) Scale Score After 28 Weeks of Treatment | -0.18 Score on a scale | Standard Deviation 0.791 |
| Placebo | Change From Baseline in Clinical Global Impressions-Severity (CGI-S) Scale Score After 28 Weeks of Treatment | -0.22 Score on a scale | Standard Deviation 0.718 |
Secondary
Change From Baseline in Personal and Social Performance Scale (PSP) Score After 28 Weeks of Treatment
Personal and Social Performance scale (PSP): The PSP is a 100-point, single item, clinician rated scale to assess 4 domains of social functioning (Four domains over the past month: (1) socially useful activities, (2) personal and social relationships, (3) self-care and (4) disturbing and aggressive behaviors.) in patients with schizophrenia. The PSP score is a single score ranging from 1 to 100. Higher scores represent better personal and social functioning.
Time frame: At baseline and at Week 28
Population: Full analysis set (FAS): the FAS includes all patients in the treated set with at least 1 baseline and post-baseline measurement of any type. Only participants with non-missing results were included in the analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| BI 409306 25 mg | Change From Baseline in Personal and Social Performance Scale (PSP) Score After 28 Weeks of Treatment | 2.8 Score on a scale | Standard Deviation 8.8 |
| BI 409306 50 mg | Change From Baseline in Personal and Social Performance Scale (PSP) Score After 28 Weeks of Treatment | 2.4 Score on a scale | Standard Deviation 9.4 |
| BI 409306 Pooled | Change From Baseline in Personal and Social Performance Scale (PSP) Score After 28 Weeks of Treatment | 2.6 Score on a scale | Standard Deviation 9.1 |
| Placebo | Change From Baseline in Personal and Social Performance Scale (PSP) Score After 28 Weeks of Treatment | 3.0 Score on a scale | Standard Deviation 10.2 |
Secondary
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Positive Symptoms Score After 28 Weeks of Treatment
Positive and Negative Syndrome Scale (PANSS): assesses the severity of psychotic symptoms and progression of disease. The PANSS positive symptoms score is the sum of scores from 7 Items where each item has a minimum score 1 (better outcome) and maximum score 7 (worse outcome). The PANSS positive symptoms score ranges from 7 (less severe the disease) to 49 (more severe the disease).
Time frame: At baseline and at Week 28.
Population: Full analysis set (FAS): the FAS includes all patients in the treated set with at least 1 baseline and post-baseline measurement of any type. Only participants with non-missing results were included in the analysis.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| BI 409306 25 mg | Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Positive Symptoms Score After 28 Weeks of Treatment | -0.54 Score on a scale |
| BI 409306 50 mg | Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Positive Symptoms Score After 28 Weeks of Treatment | -0.71 Score on a scale |
| BI 409306 Pooled | Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Positive Symptoms Score After 28 Weeks of Treatment | -0.61 Score on a scale |
| Placebo | Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Positive Symptoms Score After 28 Weeks of Treatment | -0.92 Score on a scale |
p-value: 0.528995% CI: [-0.809, 1.57]Mixed model with repeated measurements
p-value: 0.74495% CI: [-1.055, 1.475]Mixed model with repeated measurements
p-value: 0.565995% CI: [-0.745, 1.358]Mixed model with repeated measurements
Secondary
Incidence Rate of New Prescription or Increase in Dose of an Ongoing Antipsychotic Medication
The incidence rate of new prescription or increase in dose of an ongoing antipsychotic medication is reported. For each treatment group, the incidence rate was calculated as the number of events / sum of the observational time (patient year) over all participants in this treatment group.
Time frame: 28 weeks
Population: Full analysis set (FAS): the FAS includes all patients in the treated set with at least 1 baseline and post-baseline measurement of any type.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| BI 409306 25 mg | Incidence Rate of New Prescription or Increase in Dose of an Ongoing Antipsychotic Medication | 0.168 Events per patient-years |
| BI 409306 50 mg | Incidence Rate of New Prescription or Increase in Dose of an Ongoing Antipsychotic Medication | 0.130 Events per patient-years |
| BI 409306 Pooled | Incidence Rate of New Prescription or Increase in Dose of an Ongoing Antipsychotic Medication | 0.149 Events per patient-years |
| Placebo | Incidence Rate of New Prescription or Increase in Dose of an Ongoing Antipsychotic Medication | 0.217 Events per patient-years |
p-value: 0.636295% CI: [0.293, 2.118]Regression, Cox
p-value: 0.378295% CI: [0.205, 1.826]Regression, Cox
p-value: 0.425395% CI: [0.296, 1.671]Regression, Cox
Secondary
Incidence Rate of Suicidal Ideation and Behaviour (Assessed by Columbia Suicide Severity Rating Scale (C-SSRS)) After 28 Weeks of Treatment
Columbia Suicide Severity Rating Scale (C-SSRS): suicide risk assessment. At a minimum, the interview consists of 2 screening questions related to suicidal ideation and 4 related to suicidal behavior, and may be expanded to up to 17 items in case of positive responses. Free text entries are allowed. Suicidal behavior is collected in nominal scale as presence/absence of actual attempts, non-suicidal self-injurious behavior, interrupted attempts, aborted attempts, preparatory acts or behavior, and any suicidal behavior. Suicidal ideation is rated on a 6-point scale from 0 (No ideation present) to 5 (Active ideation with plan and intent). A score of 4 or 5 on this scale indicates serious suicidal ideation. For each treatment group, the incidence rate was calculated as the number of events / sum of the observational time (patient year) over all participants in this treatment group.
Time frame: 28 weeks
Population: Full analysis set (FAS): the FAS includes all patients in the treated set with at least 1 baseline and post-baseline measurement of any type.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| BI 409306 25 mg | Incidence Rate of Suicidal Ideation and Behaviour (Assessed by Columbia Suicide Severity Rating Scale (C-SSRS)) After 28 Weeks of Treatment | 0.070 Events per patient-years |
| BI 409306 50 mg | Incidence Rate of Suicidal Ideation and Behaviour (Assessed by Columbia Suicide Severity Rating Scale (C-SSRS)) After 28 Weeks of Treatment | 0.077 Events per patient-years |
| BI 409306 Pooled | Incidence Rate of Suicidal Ideation and Behaviour (Assessed by Columbia Suicide Severity Rating Scale (C-SSRS)) After 28 Weeks of Treatment | 0.073 Events per patient-years |
| Placebo | Incidence Rate of Suicidal Ideation and Behaviour (Assessed by Columbia Suicide Severity Rating Scale (C-SSRS)) After 28 Weeks of Treatment | 0.071 Events per patient-years |
p-value: 0.993895% CI: [0.203, 4.989]Regression, Cox
p-value: 0.89395% CI: [0.225, 5.531]Regression, Cox
p-value: 0.93695% CI: [0.265, 4.233]Regression, Cox
Secondary
Patient Global Impressions-Improvement (PGI-I) Scale Score After 28 Weeks of Treatment
Patient Global Impressions-Improvement (PGI-I): One-item evaluation completed by the patient to assess their overall evaluation of his/her status compared to how they felt at randomisation. The PGI-I score ranges from 1 (Very much better) through to 7 (Very much worse). The higher the score, the worse the improvement.
Time frame: At Week 28
Population: Full analysis set (FAS): the FAS includes all patients in the treated set with at least 1 baseline and post-baseline measurement of any type. Only participants with non-missing results were included in the analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| BI 409306 25 mg | Patient Global Impressions-Improvement (PGI-I) Scale Score After 28 Weeks of Treatment | 2.61 Score on a scale | Standard Deviation 1.328 |
| BI 409306 50 mg | Patient Global Impressions-Improvement (PGI-I) Scale Score After 28 Weeks of Treatment | 2.96 Score on a scale | Standard Deviation 1.197 |
| BI 409306 Pooled | Patient Global Impressions-Improvement (PGI-I) Scale Score After 28 Weeks of Treatment | 2.76 Score on a scale | Standard Deviation 1.28 |
| Placebo | Patient Global Impressions-Improvement (PGI-I) Scale Score After 28 Weeks of Treatment | 2.94 Score on a scale | Standard Deviation 1.19 |